BRAF and cancer: BRAF mutations have been found in KMT2A-rearranged AML and ALL (Fig. 2 and Supplemental Table 1, Supplemental Digital Content).29,34,36 Most cancer-associated BRAF mutations encode gain-of-function mutants that constitutively activate the kinase and the MEK–ERK pathway.